COVID-19 preclinical drug development database

Nanobodies

Rosalind Franklin Institute

Added 15/05/2020 | Updated 05/10/2021

Back

Project Details

Type of project

  • Tier 3: discovering and categorising new molecules
  • Supporting technologies, models and assays

Therapeutic target

  • Preventing infection (prophylaxis or preventing cell entry)
  • Preventing virus replication in early disease
  • Preventing death (respiratory failure, shock or multiple organ failure)

Type of supporting technology

  • Non-therapeutic antibodies
  • Assays and protocols (eg. for virus detection)

Phase of project

Modality (if can be disclosed)*

  • Nanobodies or fragments (eg. Fab)

Molecular/cellular target (if known or can be disclosed)*

  • SARS-CoV-2 Spike protein

Partner institutions/organisations

  • Oxford University
  • Diamond Light Source

Key contact

Name: Professor James Henderson Naismith

Email Address: naismith@strubi.ox.ac.uk

Phone Number:

Key Collaborators:

Anticipated timeframe of future outputs

1-3 months

This research project is looking for the following:

neutralisation, animal models and clinical trials

Further Details

Abstract or additional information (if available)*

We have nM nanobodies to the Spike protein. We are still waiting for neutralisation data

Published outputs (if available)*

Relevant weblinks